Patents by Inventor Balwinder Singh

Balwinder Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6958399
    Abstract: Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.
    Type: Grant
    Filed: May 25, 2004
    Date of Patent: October 25, 2005
    Assignee: Targacept, Inc.
    Inventors: William Scott Caldwell, Gary Maurice Dull, Balwinder Singh Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared Miller Wagner, Peter Anthony Crooks
  • Patent number: 6890935
    Abstract: The present invention relates to aryl olefinic azacyclic compounds and aryl acetylenic azacyclic compounds, including pyridyl olefinic cycloalkylamines and pyridyl acetylenic cycloalkylamines. The present invention also relates to prodrug derivatives of the compounds of the present invention.
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: May 10, 2005
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, Jeffrey Daniel Schmitt, Balwinder Singh Bhatti, Craig Harrison Miller
  • Publication number: 20040214835
    Abstract: Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.
    Type: Application
    Filed: May 25, 2004
    Publication date: October 28, 2004
    Inventors: William Scott Caldwell, Gary Maurice Dull, Balwinder Singh Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared Miller Wagner, Peter Anthony Crooks
  • Publication number: 20040152723
    Abstract: Pharmaceutical compositions incorporate compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the central and autonomic nervous systems can be treated using pharmaceutical compositions incorporating compounds in which an aromatic ring is bridged with an ethylenic or acetylenic unit to an azabicyclic moiety.
    Type: Application
    Filed: September 23, 2003
    Publication date: August 5, 2004
    Inventors: Thomas Jeffrey Clark, Balwinder Singh Bhatti
  • Publication number: 20040048806
    Abstract: The invention provides an in vivo method whereby female offsprings can be produced in mammals, especially in bovine species said method comprising the step of administering a therapeutically effective amount of a material comprising acetic acid, or its pharmaceutically acceptable derivatives to female mammals just after or before insemination
    Type: Application
    Filed: July 31, 2003
    Publication date: March 11, 2004
    Inventor: Balwinder Singh Aulakh
  • Patent number: 6627648
    Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines and arylthioalkylamines, including pyridyloxyl-alkylamines, phenoxyalkylamines, pyridylthiolalkylamines and phenylthio-alkylamines. Exemplary compounds include (2-(5-bromo(3-pyridylthio))-ethyl)methylamine, (2-(5-bromo(3-pyridylthio))isopropyl)methylamine, (2-(5-bromo(3-pyridylthio))propyl)methylamine, (3-(5-bromo(3-pyridylthio))-propyl)methylamine, 3-((3S)-3-pyrrolidinyloxy)pyridine, 3-(4-piperidinyloxy)pyridine, 3-(1-methyl-4-piperidinyloxy)pyridine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, and methyl(3-tricyclo[7.3.1.0<5,13>]tridec-2-yloxypropyl)amine.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: September 30, 2003
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, Erin E. Reich, Jared Miller Wagner, Balwinder Singh Bhatti, Michael B. Consilvio
  • Patent number: 6624167
    Abstract: Pharmaceutical compositions incorporate compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the central and autonomic nervous systems can be treated using pharmaceutical compositions incorporating compounds in which an aromatic ring is bridged with an ethylenic or acetylenic unit to an azabicyclic moiety.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: September 23, 2003
    Assignee: Targacept, Inc.
    Inventors: Thomas Jeffrey Clark, Balwinder Singh Bhatti
  • Patent number: 6624173
    Abstract: Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo [2.2.2]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.
    Type: Grant
    Filed: June 30, 1997
    Date of Patent: September 23, 2003
    Assignee: Targacept, Inc.
    Inventors: Peter Anthony Crooks, Gary Maurice Dull, William Scott Caldwell, Balwinder Singh Bhatti, Niranjan Madhukar Deo, Alain Ravard
  • Patent number: 6579878
    Abstract: Pharmaceutical compositions incorporate compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the central and autonomic nervous systems can be treated using pharmaceutical compositions incorporating compounds in which an aromatic ring is bridged with an alkylene or alkylidene unit to an azabicyclic moiety.
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: June 17, 2003
    Assignee: Targacept, Inc.
    Inventors: Balwinder Singh Bhatti, Thomas Jeffrey Clark, Craig H. Miller, Jeffrey Daniel Schmitt
  • Publication number: 20030087915
    Abstract: Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (2S)-(4E)-N-methyl-5-[3-(5-isopropoxy-1-oxopyridin)yl)]-4-penten-2-amine, (4E)-N-methyl-5-(3-(1-oxopyridin)yl)4-penten-2-amine, (4E)-N-methyl-5-(3-(5-((carboxymethyl)oxy)pyridin)yl)-4-penten-2-amine and (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine.
    Type: Application
    Filed: September 16, 2002
    Publication date: May 8, 2003
    Inventors: Gary Maurice Dull, Craig Harrison Miller, William Scott Caldwell, Dwo Lynm, Balwinder Singh Bhatti, Jeffrey Daniel Schmitt, Gary Dwight Byrd
  • Patent number: 6455554
    Abstract: Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (2S)-(4E)-N-methyl-5-[3-(5-isopropoxy-1-oxopyridin)yl)]-4-penten-2-amine, (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-((carboxymethyl)oxy)pyridin)yl)-4-penten-2-amine and (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: September 24, 2002
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, Craig Harrison Miller, William Scott Caldwell, Dwo Lynm, Balwinder Singh Bhatti, Jeffrey Daniel Schmitt, Gary Dwight Byrd
  • Patent number: 6452418
    Abstract: A driving circuit provides a symmetric differential driving signal relative to one set of voltage potentials to a driver circuit that drives an output node to another set of voltage potentials. The differential driving signals from the driving system are equal and opposite to each other, thereby avoiding stray current flow between the driving system and the driven current mirrors. The transistors that provide the driving signal are continuously biased, using a weak bias in one logic state and stronger bias in the other state, to avoid hard-switching transients.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: September 17, 2002
    Assignee: Koninklijke Philips Electronics N.V.
    Inventors: Balwinder Singh, Klaas-Jan De Langen, Martijn Bredius
  • Patent number: 6417359
    Abstract: A compound having the formula: wherein X′ is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0, but not equal to 0; A, A′ and A″ are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z′ is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z″ is hydrogen or a substituent other than hydrogen; Y is C═O, C(OH)R′ or C—A, where R′ is hydrogen or lower alkyl.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: July 9, 2002
    Assignee: Targacept, Inc.
    Inventors: Peter Anthony Crooks, Haeil Park, Balwinder Singh Bhatti, William Scott Caldwell, Gary Maurice Dull
  • Publication number: 20020058652
    Abstract: The present invention relates to aryl olefinic azacyclic compounds and aryl acetylenic azacyclic compounds, including pyridyl olefinic cycloalkylamines and pyridyl acetylenic cycloalkylamines. The present invention also relates to prodrug derivatives of the compounds of the present invention.
    Type: Application
    Filed: April 30, 2001
    Publication date: May 16, 2002
    Inventors: Gary Maurice Dull, Jeffrey Daniel Schmitt, Balwinder Singh Bhatti, Craig Harrison Miller
  • Publication number: 20020052497
    Abstract: Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.
    Type: Application
    Filed: October 9, 2001
    Publication date: May 2, 2002
    Applicant: Targacept, Inc.
    Inventors: William Scott Caldwell, Gary Maurice Dull, Balwinder Singh Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared Miller Wagner, Peter Anthony Crooks
  • Patent number: 6337351
    Abstract: Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (4E)-N-methyl-5-(3-acetamido-4-methylphenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-amino-4-methylphenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(dimethylamino)phenyl)-4-penten-2-amine, (4E)-N-methyl-5-(4-methyl-3-nitrophenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-fluorophenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3,4-dichlorophenyl)-4-penten-2-amine and (4E)-N-methyl-5-(3,4-methylenedioxyphenyl)-4-penten-2-amine.
    Type: Grant
    Filed: September 8, 1999
    Date of Patent: January 8, 2002
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, Jared Miller Wagner, William Scott Caldwell, Craig Harrison Miller, Jeffrey Daniel Schmitt, Balwinder Singh Bhatti, Srishailkumar Basawannappa Hadimani
  • Patent number: 6310102
    Abstract: Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (E)-4-(3-aminophenyl)-3-buten-1-amine, (E)-N-methyl-4-(3-aminophenyl)-3-buten-1-amine and (E)-N-methyl-5-(3-aminophenyl)-4-penten-2-amine.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: October 30, 2001
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, Jared Miller Wagner, William Scott Caldwell, Craig Harrison Miller, Jeffrey Daniel Schmitt, Balwinder Singh Bhatti, Srishailkumar Basawannappa Hadimani
  • Patent number: 6262124
    Abstract: Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (E)-4-(3-aminophenyl)-3-buten-1-amine, (E)-N-methyl-4-(3-aminophenyl)-3-buten-1-amine and (E)-N-methyl-5-(3-aminophenyl)-4-penten-2-amine.
    Type: Grant
    Filed: October 22, 1998
    Date of Patent: July 17, 2001
    Inventors: Gary Maurice Dull, Jared Miller Wagner, William Scott Caldwell, Craig Harrison Miller, Jeffrey Daniel Schmitt, Balwinder Singh Bhatti, Srishailkumar Basawannappa Hadimani
  • Patent number: 6057446
    Abstract: A compound having the formula: ##STR1## wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0, but not equal to 0; A, A' and A" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z" is hydrogen or a substituent other than hydrogen; Y is C.dbd.O, C(OH)R' or C--A, where R' is hydrogen or lower alkyl.
    Type: Grant
    Filed: April 2, 1998
    Date of Patent: May 2, 2000
    Inventors: Peter Anthony Crooks, Haeil Park, Balwinder Singh Bhatti, William Scott Caldwell, Gary Maurice Dull
  • Patent number: 5726316
    Abstract: Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-N-methyl-4-?3-(6-methylpyrindin)yl!-3-butene-1-amine and N-methyl-4-(3-pyridinyl)-3-butyne-1-amine.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: March 10, 1998
    Inventors: Peter Anthony Crooks, William Scott Caldwell, Gary Maurice Dull, Balwinder Singh Bhatti, Niranjan Madhukar Deo, Alain Ravard